FDA Clears C2N Diagnostics' PrecivityAD2 Blood Test for Alzheimer's in Adults as Young as 40
核心洞察
The U.S. FDA cleared C2N Diagnostics (搜索)' PrecivityAD2 (搜索) blood test for adults as young as 40 experiencing signs of cognitive impairment, making it the first FDA-cleared Alzheimer's blood test available to patients this young.
The clearance builds on nearly 20 years of Alzheimer's Drug Discovery Foundation (搜索) (ADDF) investment in C2N's science, including a $7 million investment through its Diagnostics Accelerator.
PrecivityAD2 (搜索) detects amyloid (搜索) plaques in the brain with high diagnostic accuracy and is also being integrated into UK primary care pathways through the BEAD-PC study at Imperial College London.
The U.S. Food and Drug Administration has cleared C2N Diagnostics (搜索)' PrecivityAD2 (搜索) blood test for use in adults as young as 40 who are experiencing signs of cognitive impairment, making it the first FDA-cleared Alzheimer's blood test available to patients this young. The clearance builds on nearly 20 years of Alzheimer's Drug Discovery Foundation (搜索) (ADDF) investment in C2N's science and reflects the growing momentum of blood-based diagnostics in bringing earlier, more accurate detection into mainstream care.
"Today's clearance reflects how rapidly the field is advancing. Just over a year ago, there were no FDA-cleared blood tests for Alzheimer's and now we have three," said Isobel Coleman, Chief Executive Officer of the ADDF. "This is a proof point that sustained, early investment in translational science plays a catalytic role in moving promising ideas from the lab to patients."
A Two-Decade Investment in Blood-Based Biomarkers
The ADDF's partnership with C2N Diagnostics (搜索) began in 2008 with early seed funding that catalyzed the development of PrecivityAD, the first blood test to help diagnose Alzheimer's. This support has continued, including a $7 million investment through the ADDF's Diagnostics Accelerator (DxA), helping to establish blood-based biomarkers as a cornerstone of modern Alzheimer's research and care.
The field has long recognized that Alzheimer's pathology can begin 15 to 20 years before symptoms appear. Closing that gap has been a key focus of the ADDF's work, and validated tools that reach patients earlier, including those in their 40s and 50s, help pave the way for earlier detection and, ultimately, earlier treatment.
Clinical Utility and Diagnostic Accuracy
The PrecivityAD2 (搜索) test detects amyloid (搜索) plaques in the brain with high diagnostic accuracy and is indicated for patients 50 and older with signs or symptoms of mild cognitive impairment or dementia. The FDA clearance extends availability to adults as young as 40 experiencing signs of cognitive impairment.
"PrecivityAD2 (搜索) reflects how far biomarker science has come, and it points to an even bigger opportunity ahead," said Laura Nisenbaum, PhD, Interim Chief Science Officer at the ADDF. "Tests like this don't just help to diagnose Alzheimer's, they can also identify the right patients for a clinical trial and confirm whether a drug is engaging its target."
Dr. Nisenbaum noted that this precision is already reshaping trial design, with 83% of active Alzheimer's trials now incorporating a biomarker. "As we validate the next generation of tools, we will move closer to the same transformative approach already common in cancer care: being able to match the right drugs to the right patient at the right time," she added.
Integration Into Primary Care Pathways
Beyond its U.S. regulatory milestone, PrecivityAD2 (搜索) is being integrated into clinical care pathways in the United Kingdom. Through C2N's partnership with the Davos Alzheimer's Collaborative (DAC), Imperial College London is the only UK center participating in the Accurate Dx program, which also includes four health systems in the United States, two in the European Union, and one in Japan.
At the Imperial site, the Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer's Disease (搜索) in Primary Care (BEAD-PC) study has participating general practitioners in North West London using the PrecivityAD2 (搜索) test in addition to standard cognitive assessments prior to referral to dementia specialists at Imperial College Healthcare NHS Trust. The UK study started recruiting patients in May.
Dr. Lefkos Middleton, Professor of Neurology at Imperial, said, "The recent emergence of blood-based biomarkers having comparable sensitivity and specificity to highly specialized imaging and cerebrospinal fluid tests has been a major breakthrough in the field of Alzheimer's disease (搜索)."
The study is designed around testing the accuracy of PrecivityAD2 (搜索) in primary care pathways for dementia diagnosis, placing this new technological approach directly within primary care research sites rather than in hospital or specialist settings, for a quicker and more accurate diagnosis early in disease stages. Those whose results suggest early-stage cognitive impairment are referred to the Imperial Memory Unit at Charing Cross Hospital for further specialist evaluation.
Addressing the Diagnostic Gap
Beyond its immediate clinical aims, the BEAD-PC study is designed to generate evidence that could inform how Alzheimer's diagnostics are delivered at scale across the National Health Service and other healthcare systems worldwide. By testing the integration of high-performance blood-based biomarker testing into routine general practitioner appointments, the study seeks to address one of the most persistent challenges in dementia care: the gap between the onset of disease and the point at which it is formally diagnosed.
Professor David Wingfield, Professor of Practice at Imperial, said, "For too long general practitioners have operated in a 'grey area' where they respond to patient concerns without precise tools to define the nature of the disease process. For Alzheimer's disease (搜索) we now have the tools in the form of blood biomarkers, which are easier for patients and help define the nature of the condition and point towards treatments that may help."
A New Era of Precision Medicine
Today's decision follows the FDA's clearance of Fujirebio's Lumipulse blood test, another ADDF-funded diagnostic, underscoring how early investment is driving a new generation of Alzheimer's blood tests for clinical use. PrecivityAD2 (搜索) is part of the ADDF's robust diagnostics portfolio, which includes 47 active programs spanning seven different pathways.
The ADDF is focused on advancing the next generation of biomarkers, including blood tests for tau and other mixed pathologies, multi-marker panels, AI-driven approaches, and diagnostics that reflect the broader pathobiology of the disease, which are key to enabling more precise treatment strategies tailored to individual patients. As PrecivityAD2 (搜索) and tools like it move further into clinical practice, they will enable earlier detection, sharpen clinical trials, and build the foundation for precision medicine and combination therapies.